07:23 AM EST, 11/03/2026 (MT Newswires) -- BioNTech (22UA.F) upgraded its non-IFRS revenue guidance for full-year 2026 with its latest earnings update, according to a Tuesday filing. The German drugmaker expects revenue for the year ending Dec. 31 of between 1.70 billion euros and 1.90 billion euros, compared with its previous outlook of 1.60 billion euros to 1.90 billion euros.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.